Journal of Korean Neuropsychiatric Association (신경정신의학)

Korean Neuropsychiatric Association (대한신경정신의학회)
권호 표지

The Korean Version of 4th Revision of Schizophrenia Quality of Life Scale：Validation Study and Relationship with PANSS

한국어판 정신분열병 삶의 질 척도의 개발과 PANSS와의 관련성

Kim, Jin-Hun;Im, Seon-Jin;Min, Seong-Gil;Kim, Seung-Eop;Son, So-Jeong;Wild, Diane J;Park, Seong-Hyeok;Lee, Hwang-Bin
김진훈;임선진;민성길;김승업;손소정;;박성혁;이황빈

  • Published : 20060000
⟨ Previous Next ⟩

Abstract

Objectives：The present study was performed to verify the validity and value of 4th revision of Schizophrenia Quality of Life Scale (SQLS-R4) as an assessment tool in a Korean-language version (SQLS-R4K). Methods：The subjects for present study were 174 patients with a diagnosis of schizophrenia as defined by DSM-IV. The SQLS-R4K was administered together with self-report Korean version of World Health Organization Quality of Life-Brief Scale (WHOQOL-BREF) to assess validity. A subset of respondents also completed the SQLS-R4K for a second time to assess testretest reliability. To evaluate the relationship SQLS-R4K and clinical characteristics, psychotic symptoms and general functioning were evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning Scale (GAF) score respectively. Results：All the scales of SQLS-R4K showed good internal consistency reliability. The correlations of items with their scale total revealed that all items were significantly correlated with their own scale score. In test-retest reliability, paired t-tests indicated that responses did not alter significantly between the two assessment. There was moderate correlation between WHOQOL-BREF sub-scores and SQLS-R4K score total. Also relevant correlations between PANSS, current GAF and SQLS-R4K were proved. Conclusion：From the results of the testing the reliability and validity of the SQLS-R4K, it is concluded that the SQLS-R4K is a simple and reliable scale for measuring quality of life in schizophrenic patients. (J Korean Neuropsychiatr Assoc 2006;45(5): 401-410)

SQLS-R4K는 신뢰성과 타당성을 지닌 우수한 정신분열병 환자에 특이한 주관적 삶의 질 측정도구라는 것을 알 수 있었다. 또한 간단하며 정신분열병 환자가 비교적 쉽게 작성이 가능하여 임상 연구나 임상 진료에 있어서도 일상적 으로 사용하기에도 편리하기에 추후 정신분열병 환자의 삶의 질 측정에서 유용하게 사용되리라 기대된다.

Keywords

References

  1. Norman RM, Malia AK, McLean T, Voruganti LP, Cortese L, McIntosh E. et aL The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of Life Scale. Acta Psychiatr Scand 2000;102:303-309 https://doi.org/10.1034/j.1600-0447.2000.102004303.x
  2. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999;60:32-35
  3. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-1887 https://doi.org/10.1176/appi.ajp.162.10.1879
  4. Cramer JA, Rosenhack R, Xu W, Thomas J, Henderson W, Chamey DS. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Clinperative Study Group on Clozapine in refractory schizophrenia. Schizophr Bull 2000:26:659-666 https://doi.org/10.1093/oxfordjournals.schbul.a033484
  5. Lima MS, Mari JJ, Breier A, Costa AM, Sena EP, Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry 2005;66:831-838 https://doi.org/10.4088/JCP.v66n0704
  6. Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turnaer MS, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005;19:5-14
  7. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18:5-17 https://doi.org/10.2165/00023210-200418002-00002
  8. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use 3rd Ed. Oxford university press, New York;2003
  9. Wilkinson G, Hesdon B, Wild D, Clinkson R, Farina C, Sharma V, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000;177:42-46 https://doi.org/10.1192/bjp.177.1.42
  10. Foster K. Review of Protocol. Paliperidone palmitate investigator meeting R092670 PSY-3001. 2005;Geneva, Switzerland
  11. Ahn YM. Review of protocol. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with long acting risperidone microspheres. Seoul, Korea;2005
  12. Fitzgerald PB, Williams CL, Corteling N, Filla SL, Brewer K, Adams A, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 2001;103:387-392 https://doi.org/10.1034/j.1600-0447.2001.00254.x
  13. Bjorner JB, Fayers P, Idler E. Self-rated health. In: Assessing quality of life in clinical trials 2nd Ed. Ed by Fayers P, Hays R. Oxford University Press, New York;2005
  14. American Psychiatric Association. DSM-IV: Diagnostic and statistical manual of mental disorder. 4th ed. American Psychiatric Association, Washington DC:1994
  15. Carmines EG, Zeller RA. Reliability and Validity Assessment. Sage, Beveeley Hills, CA;1979
  16. Min SK, Lee CI, Kim KI, Sub SY, Kim DK. Development of Korean version of WHO quality of life scale abbreviated version (WHOQOL-BREF). J Korean Neuropsychiatr Assoc 2000;39:571-579
  17. The World Health Organization Quality of Life assessment (WHO-QOL): position paper from the World Health Organization. Soc Sci Med 1995;41:1403-1409 https://doi.org/10.1016/0277-9536(95)00112-K
  18. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. The WHOQOL Group. Psychol Med 1998;28:551-558 https://doi.org/10.1017/S0033291798006667
  19. Min SK, Park JK, Sub SY, Kim DK. Effects of haloperidol and risperidone on the subjective quality of life in stable chronic schizophrenic patients. J Korean Neuropsychiatr Assoc 2002;41 :76-83
  20. Kim YH, Yun KW, Kim MK, Lee HJ. A study on depression, anxiety and quality of life in amenorrhea schizophrenics treated with risperidone. J Korean Neuropsychiatr Assoc 2004:43:537-545
  21. Kay SR, Fiszbein A, Olper LA. The Positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;6: 118-124
  22. Yi JS, Chung MH, Lee BW, Lee SI. Reliability and validity of the Korean version of global assessment of functioning scale. Schizophrenia Clinics 2003;6:118-124
  23. Awad G, Voruganti LNP. Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull 2000;26: 557-564 https://doi.org/10.1093/oxfordjournals.schbul.a033477
  24. Hofer A, Kmmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004;65:932-93 https://doi.org/10.4088/JCP.v65n0709
  25. Gaite L, Vazquez-Barquero JL, Borra C, Ballesteros J, Schene A, Welcher B, et al. Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand 2002;105:283-292 https://doi.org/10.1034/j.1600-0447.2002.1169.x
  26. Koivumaa-Honkanen HT, Viinamaki H, Honkanen R, Tanskanen A, Antikainen R, Niskanen L, et al. Correlates of life satisfaction among psychiatric patients. Acta Psychiatr Scand 1996;94:372-378 https://doi.org/10.1111/j.1600-0447.1996.tb09875.x
  27. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 2001;51:171-180 https://doi.org/10.1016/S0920-9964(99)00151-6
  28. Sub HS, Kim CH, Lee HS, Jung YC, Choi YH, Lee C. Quality of life and psychopathology in patients with schizophrenia: Subjective and objective assessment. J Korean Neuropsychiatr Assoc 2001:40:1122-1131
  29. Patterson TL, Shaw W. Semple SJ, Moscona S, Harris MJ, Kaplan Rm, et al. Health-related quality of life in older patients. Intl J Geriatr Psychiatry 1997;12:452-461 https://doi.org/10.1002/(SICI)1099-1166(199704)12:4<452::AID-GPS500>3.0.CO;2-S
  30. Moller HJ, Liorca PM, Sacchetti E, Martin SD, Medori R, Parellada E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20: 121-130 https://doi.org/10.1097/00004850-200505000-00001
  31. Norman RMG, Malla AK. Dysphoric mood and symptomatology in schizophrenia. Psychological Med 1991:21:897-903 https://doi.org/10.1017/S0033291700029883
  32. Norman RMG, Malla AK, Cortese L, Diaz F. Aspects of dysphoria and symptoms in schizophrenia. Psychological Med 1998;28:1433-1441 https://doi.org/10.1017/S003329179800751X
  33. Kunikata H, Mino Y, Nakajima K. Quality of life of schizophrnic patients living in the community: the relationships with personal characteristics, objective indicators and self-esteem. Psychiatry Clin Neurosci 2005;59:163-169 https://doi.org/10.1111/j.1440-1819.2005.01352.x
  34. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two year outcome in first episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998:155:1196-1201 https://doi.org/10.1176/ajp.155.9.1196
  35. Packer S, Husted J, Cohen S, Tomlinson G. Psychopathology and quality of life in schizophrenia. J psychiatry Neurosci 1997:22:231-234
  36. Pinikahana J, Happell B, Hope J, Keks NA. Quality of life in schizophrenia: a review of literature from 1995 to 2000. Int J Ment Health Nurs 2002;11:103-111 https://doi.org/10.1046/j.1440-0979.2002.00233.x
  37. Kim JH, Yoon JH, Lee JY, No KH, Hong SK, Yoon SC, et al. Subjective quality of life in schizophrenic patients receiving atypical antipsychotics: Relationship to psychopathology, adverse drug effects and subjective respanse to drug. J Korean Neuropsychiatr Assoc 2003;42:223-230
  38. Joo YH, Kim YS, Jeong SH, Shin MS, Lee CI. Relationships between subjective symptoms and objective psychopathology in patients with schizophrenia. J Korean Neuropsychiatr Assoc 2001;40:667-678